People with anorexia nervosa, paradoxically, have strikingly high levels of fat within their bone marrow, report researchers at Children's Hospital Boston. Their findings, based on MRI imaging of the knees of 20 girls with anorexia and 20 healthy girls of the same age, appear in the February issue of the Journal of Bone and Mineral Research. "It's counter-intuitive that an emaciated young woman with almost no subcutaneous fat would be storing fat in her marrow, " says endocrinologist Catherine Gordon, MD, MSc, director of the Bone Health Program at Children's and the study's senior investigator. In the study, the knee MRI images were read by radiologists who were unaware of the patient's clinical status.
Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown. Now, Katia Scotlandi and colleagues, at SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy, have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS. In the study, decreasing CD99 expression in human EWS cell lines reduced their ability to form tumors xenografted into mice. In vitro, it increased expression of H-neurofilament, a marker of neuronal differentiation.
Denosumab is a targeted therapy to prevent bone loss. It stops progressive bone destruction and tumour spread in some patients with inoperable giant-cell tumour (GCT) of bone. An article published Online First in The Lancet Oncology reports this could change standard treatment practice. Breaking new ground, this work is the first to clearly show a promising systemic treatment option for this rare type of bone tumour. GCT can be limb and life threatening. It causes pain, impaired function and mobility. This condition is usually benign, and surgery is the standard treatment. However, GCT can become malignant after radiation therapy or several recurrences.
Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine, " to raise awareness of osteoarthritis, increase public health education and support breakthrough research. "Like the Arthritis Foundation, we are focusing our extensive clinical and research resources on raising awareness of the potentially debilitating effects of osteoarthritis in this country, " said Stephen Paget, M.D., physician-in-chief and chair of the division of rheumatology at HSS. "We applaud the efforts of the Arthritis Foundation and the Ad Council as they begin a multi-year initiative to improve the understanding of osteoarthritis, and we join them with our commitment to identify better methods to diagnose, treat and prevent the disease, " Dr.
The American Academy of Orthopaedic Surgeons (AAOS) recently approved and released an evidence-based clinical practice guideline on the Treatment of Distal Radius Fractures. A distal radius fracture - one of the most common fractures in the body - usually occurs as a result of a fall. For example, a fall may cause someone to land on his or her outstretched hands, breaking the larger of the two bones in the forearm, near the wrist. In 2007, more than 261, 000 people visited the emergency room due to a distal radius fracture. "The Academy created this clinical practice guideline to improve patient care for those sustaining a distal radius fracture, " stated David Lichtman, MD, chair of this guideline workgroup.
Denosumab Demonstrated Superiority Over Zometa R In Pivotal Phase 3 Head-to-Head Trial In Prostate Cancer Patients With Bone Metastases
Amgen (Nasdaq: AMGN) announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1, 901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and reducing the rate of multiple SREs (hazard ratio 0.82, 95 percent CI: 0.71, 0.94). Both results were statistically significant. Overall rates of adverse events and serious adverse events, including infections, were generally similar between the two arms.